Publications - Louis Letendre, M.D.

Back to research profile

1. Lim MY, Al-Kali A, Ashrani AA, Begna KH, Elliott MA, Hogan WJ, Hook CC, Kaufmann SH, Letendre L, Litzow MR, Patnaik MS, Pardanani A, Tefferi A, Wolanskyj AP, Grill DE, Pruthi RK. Comparison of complication rates of Hickman((R)) catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy. Leuk Lymphoma. 2012 Nov 19. [Epub ahead of print]
   View PubMed
2. Elliott MA, Letendre L, Tefferi A, Hogan WJ, Hook C, Kaufmann SH, Pruthi RK, Pardanani A, Begna KH, Ashrani AA, Wolanskyj AP, Al-Kali A, Litzow MR. Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy. Eur J Haematol. 2012 Mar; 88(3):237-43. Epub 2011 Nov 17.
   View PubMed
3. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011 Jul; 86(7):610-1. Epub 2011 May 31.
   View PubMed
4. Balin SJ, Wetter DA, Kurtin PJ, Letendre L, Pittelkow MR. Myelodysplastic syndrome presenting as generalized granulomatous dermatitis. Arch Dermatol. 2011 Mar; 147(3):331-5.
   View PubMed
5. Elliott MA, Letendre L, Gastineau DA, Winters JL, Pruthi RK, Heit JA. Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. Eur J Haematol. 2010 Jul; 85(1):43-50. Epub 2010 Mar 20.
   View PubMed
6. Elliott MA, Litzow MR, Letendre LL, Wolf RC, Hanson CA, Tefferi A, Tallman MS. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood. 2007 Dec 15; 110(13):4172-4. Epub 2007 Oct 01.
   View PubMed
7. Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM, Dispenzieri A, Gertz MA, Hayman SR, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Litzow MR. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant. 2006 Jun; 37(11):1003-8.
   View PubMed
8. Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, Tefferi A, Elliot MA, Kaufmann SH, Mesa RA, Litzow MR. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia. 2006 Jan; 20(1):29-34.
   View PubMed
9. Litzow MR, Dietz AB, Bulur PA, Butler GW, Gastineau DA, Hoering A, Fink SR, Letendre L, Padley DJ, Paternoster SF, Tefferi A, Vuk-Pavlovic S. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy. 2006; 8(3):290-8.
   View PubMed
10. Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C. Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res. 2005 Sep 15; 11(18):6641-9.
    View PubMed
11. Chen YC, Chou JM, Letendre L, Li CY. Clinical importance of bone marrow monocytic nodules in patients with myelodysplasia: Retrospective analysis of 21 cases. Am J Hematol. 2005 Aug; 79(4):329-31.
    View PubMed
12. Gore SD, Smith BD, Gojo I, Grever M, Kaufmann SH, Letendre L, Leonard DGB, Marcucci G, Miller CB, Morris L, Piantadosi S, Prior T, Stock W, Karp JE. Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia. Am J Hematol. 2005 Jun; 79(2):119-27.
    View PubMed
13. Elliott MA, Wolf RC, Hook CC, Pruthi RK, Heit JA, Letendre LL, Tefferi A, Kaufmann SH, Mesa RA, Litzow MR. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: Incidence, risk factors, and possible role of antithrombin. Leukemia & Lymphoma. 2004 Aug; 45(8):1545-9.
    View PubMed
14. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM, Rowe JM. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). J Clin Oncol. 2004 Mar 15; 22(6):1078-86.
    View PubMed
15. Chen YC, Chou JM, Ketterling RP, Letendre L, Li CY. Histologic and immunohistochemical study of bone marrow monocytic nodules in 21 cases with myelodysplasia. Am J Clin Pathol. 2003 Dec; 120(6):874-81.
    View PubMed
16. Litzow MR, Repoussis PD, Schroeder G, Schembri-Wismayer D, Batts KP, Anderson PM, Arndt CA, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Noel P, Solberg LA Jr, Letendre L, Hoagland HC. Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator. Leuk Lymphoma. 2002 Nov; 43(11):2099-107.
    View PubMed
17. Hogan WJ, Letendre L, Litzow MR, Tefferi A, Hoagland HC, Pruthi RK, Kaufmann SH. Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. Mayo Clin Proc. 2002 Aug; 77(8):760-2.
    View PubMed
18. Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM, Markovic SN. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia. 2002 Jul; 16(7):1311-8.
    View PubMed
19. Elliott MA, Letendre L, Hanson CA, Tefferi A, Dewald GW. The prognostic significance of trisomy 8 in patients with acute myeloid leukemia. Leuk Lymphoma. 2002 Mar; 43(3):583-6.
    View PubMed
20. Tack DK, Letendre L, Kamath PS, Tefferi A. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant. 2001 Nov; 28(9):895-7.
    View PubMed
21. Steensma DP, Hanson CA, Letendre L, Tefferi A. Myelodysplasia with fibrosis: a distinct entity? Leuk Res. 2001 Oct; 25(10):829-38.
    View PubMed
22. Greenlund LJS, Letendre L, Tefferi A. Acute leukemia during pregnancy: a single institutional experience with 17 cases. Leuk Lymphoma. 2001 May; 41(5-6):571-577.
    View PubMed
23. Tefferi A, Elliott MA, Steensma DP, Hook CC, Dispenzieria A, Hanson CA, Schroeder G, Letendre L. Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk Res. 2001 Feb; 25(2):183-5.
    View PubMed
24. Robles C, Kim KM, Oken MM, Bennett JM, Letendre L, Wiernik PH, O'Connell MJ, Cassileth PA. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483). Leukemia. 2000 Aug; 14(8):1349-53.
    View PubMed
25. van Der Vliet HJ, Roberson AE, Hogan MC, Morales CE, Crader SC, Letendre L, Pruthi RK. All-trans-retinoic acid-induced myositis: a description of two patients. Am J Hematol. 2000 Feb; 63(2):94-8.
    View PubMed
26. Letendre L, Noel P, White WL, Tefferi A, Litzow MR, Li CY, Schroeder G. Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C. Leuk Res. 1999 Sep; 23(9):811-5.
    View PubMed
27. Elliott MA, Letendre L, Li CY, Hoyer JD, Hammack JE. Chronic lymphocytic leukaemia with symptomatic diffuse central nervous system infiltration responding to therapy with systemic fludarabine. Br J Haematol. 1999 Mar; 104(4):689-94.
    View PubMed
28. Mongkonsritragoon W, Letendre L, Li CY. Multiple lymphoid nodules in bone marrow have the same clonality as underlying myelodysplastic syndrome recognized with fluorescent in situ hybridization technique. Am J Hematol. 1998 Nov; 59(3):252-7.
    View PubMed
29. Mongkonsritragoon W, Letendre L, Qian J, Li CY. Nodular lesions of monocytic component in myelodysplastic syndrome. Am J Clin Pathol. 1998 Aug; 110(2):154-62.
    View PubMed
30. Letendre L, Noel P, Litzow MR, Hoagland HC, Tefferi A. Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C. Am J Clin Oncol. 1998 Apr; 21(2):142-4.
    View PubMed
31. Letendre L, Moore SB. Successful pregnancy after conditioning with cyclophosphamide and fractionated total body irradiation. Med Pediatr Oncol. 1997 Feb; 28(2):147-8.
    View PubMed
32. Kaufmann SH, Gore SD, Letendre L, Svingen PA, Kottke T, Buckwalter CA, Jones RJ, Grochow LB, Burke PJ, Donehower RC, Rowinsky EK. Factors affecting topotecan sensitivity in human leukemia samples. Ann N Y Acad Sci. 1996 Dec 13; 803:128-42.
    View PubMed
33. Letendre L, Noel P, Tefferi A, Solberg LA Jr, Gastineau DA, Hoagland HC. Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia. Am J Clin Oncol. 1995 Oct; 18(5):382-4.
    View PubMed
34. Witzig TE, Letendre L, Gerstner J, Schroeder G, Mailliard JA, Colon-Otero G, Marschke RF, Windschitl HE. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial. J Clin Oncol. 1995 Aug; 13(8):2012-5.
    View PubMed
35. Letendre L, Levitt R, Pierre RV, Schroeder G, Krook JA, Mailliard JE, Morton RF, Tschetter LK. Myelodysplastic syndrome treatment with danazol and cis-retinoic acid. Am J Hematol. 1995 Apr; 48(4):233-6.
    View PubMed
36. Gertz MA, Pineda AA, Chen MG, Letendre L, Greipp PR, Solberg LA Jr, Witzig TE, Garton JP, Inwards DJ, Litzow MR, et al. Refractory and relapsing multiple myeloma treated by blood stem cell transplantation. Am J Med Sci. 1995 Mar; 309(3):152-61.
    View PubMed
37. Letendre L, Hoagland HC, Moore SB, Chen MG, Gastineau DA, Gertz MA, Habermann TM, Litzow MR, Noel P, Solberg LA Jr, et al. Mayo Clinic experience with allogeneic and syngeneic bone marrow transplantation, 1982 through 1990. Mayo Clin Proc. 1992 Feb; 67(2):109-16.
    View PubMed
38. Afessa B, Tefferi A, Hoagland HC, Letendre L, Peters SG. Outcome of recipients of bone marrow transplants who require intensive-care unit support. Mayo Clin Proc. 1992 Feb; 67(2):117-22.
    View PubMed
39. Letendre L, Hoagland HC, Gertz MA. Hemorrhagic cystitis complicating bone marrow transplantation. Mayo Clin Proc. 1992 Feb; 67(2):128-30.
    View PubMed
40. Graham DL, Tefferi A, Letendre L, Gastineau DA, Hoagland HC, Noel P. Cytogenetic and molecular detection of residual leukemic cells after allogeneic bone marrow transplantation in chronic granulocytic leukemia. Mayo Clin Proc. 1992 Feb; 67(2):123-7.
    View PubMed
41. Brecher ME, Moore SB, Letendre L. Posttransfusion purpura: the therapeutic value of p1-a1-negative platelets. Transfusion (Paris) 1990 Jun; 30:433-435.
    View PubMed
42. Lust JA, Letendre L, Thibodeau SN. Marrow hypoplasia associated with a monoclonal CD8 large granular lymphocyte proliferation: reversal with cyclophosphamide and prednisone. Am J Med. 1989 Aug; 87(2):214-7.
    View PubMed
43. Letendre L. Treatment of lymphomatoid granulomatosis: old and new perspectives. Semin Respir Med. 1989 Apr; 10:178-181.
44. Letendre L, Niedringhaus RD, Therneau TM, Gastineau DA, Goldberg RM, Gerstner JB, Mailliard JA, Gundlach WJ, Kardinal CG, Pierre RV. Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside. Med Pediatr Oncol. 1989; 17(2):79-82.
    View PubMed